Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 10, 2026 · Filed Nov 12, 2026
Palvella Therapeutics's Chief Scientific Officer sold $34K of Palvella Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$33,562
Shares × reported transaction price
5 days after results of Nov 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $168.71 on Nov 10, 2026, within 5% of its 52-week high, after a 21% rise over the previous 30 trading days
52-week range $76.43 (Feb 5, 2026) to $175.92 (Nov 6, 2026), 93% of the way up, from 250 adjusted closes. 30 trading days earlier: $139.00 on Sep 29, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Insider filing
Traded Nov 10 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Nov 10 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Jeffrey S Martini (Chief Scientific Officer) sold ~$16K of Palvella Therapeutics
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
